Venous thromboembolism (including deep vein thrombosis and pulmonary embolism) and atrial fibrillation are common conditions in Western countries. The mainstay of treatment and prevention for these diseases is fast-acting anticoagulant drugs such as heparins and vitamin K antagonists. The use of these drugs is, however, complex and demanding for both patients and physicians. Recently, new antithrombotic drugs that act directly by inhibiting activated coagulation factors such as factor X or thrombin have been developed and investigated in phase III clinical trials. The aim of this article is to review: (i) the need to develop new drugs; (ii) their efficacy/safety as demonstrated in clinical trials; (iii) the need for laboratory monitoring and (iv) the direction towards the use of these new drugs in the real-life clinical situation.
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation / A. Tripodi, G. Palareti. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - 271:6(2012), pp. 554-565.
|Titolo:||New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation|
TRIPODI, ARMANDO (Primo)
|Settore Scientifico Disciplinare:||Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica|
Settore MED/09 - Medicina Interna
Settore MED/15 - Malattie del Sangue
|Data di pubblicazione:||2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/j.1365-2796.2012.02541.x|
|Appare nelle tipologie:||01 - Articolo su periodico|